AP NEWS

Innovations in Therapeutic Approach for Cystic Fibrosis, 2018 Report - ResearchAndMarkets.com

September 19, 2018

DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Innovations in Therapeutic Approach for Cystic Fibrosis” report has been added to ResearchAndMarkets.com’s offering.

This Genetic Technology TOE depicts life sciences trends across cystic fibrosis. First-in class mRNA therapeutics with targeted delivery, novel cell types, lentiviral gene therapy, and RNA vaccines, among other therapies are profiled. Clinical trials of RNA vaccines for the cancer treatment are also depicted.

The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

Key Topics Covered:

Recent Advances in Development of Novel Treatments for Cystic Fibrosis

A First-in Class mRNA Therapeutic With Targeted Delivery Novel Cell Type that Can Revolutionize Cystic Fibrosis Treatment Collaborative Development of Lentiviral Gene Therapy Treating Pulmonary Exacerbations in Cystic Fibrosis patients

Clinical Trial Analysis and Key Contacts

Clinical Trial Analysis of RNA Vaccines for the Treatment of Cancer Key Contacts For more information about this report visit https://www.researchandmarkets.com/research/7w4h4z/innovations_in?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005765/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/19/2018 03:27 PM/DISC: 09/19/2018 03:27 PM

http://www.businesswire.com/news/home/20180919005765/en

AP RADIO
Update hourly